Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal.
Stefano BorianiRiccardo CecchinatoFabrizio CuzzocreaStefano BandieraMarco GambarottiAlessandro GasbarriniPublished in: European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2019)
Denosumab alone is effective in relieving pain, increasing the ossification and sometimes reducing the tumor volume. It can be considered an excellent solution in spine GCTs whose surgical treatment cannot be Enneking appropriate or is associated with unacceptable morbidity or loss of functions. It is still impossible to state when to safely stop the treatment. Denosumab also plays a role as preoperative protocol. These slides can be retrieved under Electronic Supplementary Material.